Arkolith/Insider Trading/MBX/Form 4

Hawryluk P. Kent

President & CEO, DirectorMBX Biosciences, Inc. (MBX) · full profile →Form 4 · filed Feb 5, 2025
Net Buying
Open-Market Buys
$535K
Open-Market Sells
$0
Net Open-Market Flow
$535K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 4, 2025Buy(P)50K$10.69$535K448K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2025Grant(A)243K—$0243K

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-014494) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML